QURE uniQure N.V.
USHealthcareAs of 2026-07-10 16:00
Why QURE matters now
uniQure N.V. (QURE) is a US stock in Healthcare. The latest InvestLog snapshot shows $42.63 with -4.16% on the session and $2.90B in market capitalization; recent performance reads 1-month +87.48% and YTD +93.44%.
The latest financial table shown here is Q1 2026, with revenue of $3.6M, net income of $-53.5M, and EPS of $-0.85. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -5.9%.
The latest indexable market news headline is "uniQure (QURE) Now Trades Above Golden Cross: Time to Buy?" from Zacks Investment Research.
Additional event context on this page matters because analyst consensus is Buy with a median target of $60.00; recent insider activity includes Potts Jeannette filing S-Sale. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
19.45
P/S
161.35
EV/EBITDA
-22.01
DCF Value
$-8.17
FCF Yield
-5.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
74.1%
Operating Margin
-1057.5%
Net Margin
-1154.4%
ROE
-145.8%
ROA
-26.8%
ROIC
-26.5%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $3.6M | $-53.5M | $-0.85 |
| Q4 2025 | $5.6M | $-37.1M | $-0.59 |
| FY 2025 | $16.1M | $-199.0M | $-3.46 |
| Q3 2025 | $3.7M | $-80.5M | $-1.38 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$53.56
Target (Median)
$60.00
Target Range
$28.00 - $70.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
1.00
uniQure N.V. operates as a specialized gene therapy company, dedicated to pioneering therapeutic solutions for individuals grappling with severe genetic and other debilitating illnesses. The firm's most advanced project, Etranacogene dezaparvovec (designated as AMT-061), is currently progressing through a crucial Phase III pivotal trial, known as HOPE-B, targeting the treatment of hemophilia B. In addition to its flagship program, uniQure is actively developing several other candidates. This includes AMT-130, a gene therapy undergoing Phase I/II clinical assessment for Huntington's disease, and AMT-060, also in Phase I/II clinical trials for hemophilia B. The company's pipeline further extends to AMT-210 for Parkinson's disease, AMT-260 aimed at temporal lobe epilepsy, and AMT-161, which addresses amyotrophic lateral sclerosis. Furthermore, AMT-240 is an early-stage, preclinical product candidate focused on autosomal dominant Alzheimer's disease. Established in 1998, uniQure N.V. maintains its corporate headquarters in Amsterdam, Netherlands.